Is Tamoxifen safe for babies and kids?

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Tamoxifen poses heightened risk.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

Tamoxifen is absolutely contraindicated during pregnancy and is classified FDA Pregnancy Category D. Animal reproductive toxicology studies showed embryolethality and teratogenicity; the estrogenic/antiestrogenic activity of tamoxifen disrupts hormonal signaling critical to fetal development. Fetal exposure to tamoxifen in early pregnancy — analogous to DES exposure — theoretically carries risk of reproductive tract abnormalities in female offspring (the 'tamoxifen daughters' concern), though human evidence is limited by the rarity of tamoxifen use during pregnancy. Case reports of tamoxifen exposure during pregnancy describe adverse pregnancy outcomes including miscarriage, fetal ambiguous genitalia, and Goldenhar syndrome (one case report). Women of reproductive age taking tamoxifen require reliable contraception; pregnancy must be excluded before starting tamoxifen and confirmed contraception must be used throughout treatment. Tamoxifen's long elimination half-life and the presence of active metabolites (endoxifen, 4-hydroxytamoxifen) mean that drug and metabolites persist for weeks after cessation; a waiting period of at least 2–3 months after stopping tamoxifen is recommended before attempting pregnancy.